128767-12-4

Basic information

• Product Name: ((±))-N-Methyl-1-(3,4-methylenedioxyphenyl)-2-butylamine hydrochloride (MBDB)
• Synonyms: ((±))-N-Methyl-1-(3,4-methylenedioxyphenyl)-2-butylamine hydrochloride (MBDB);(±)-MBDB HCl;(+\-)-MBDB hydrochloride solution;1-(1,3-benzodioxol-5-yl)-N-methylbutan-2-amine:hydrochloride
• CAS NO: 128767-12-4
• Molecular Formula: C12H18ClNO2
• Molecular Weight: 243.72982
• Product Categories: Amines;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 128767-12-4.mol

Chemical Properties

• Flash Point: 9℃
• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: ((±))-N-Methyl-1-(3,4-methylenedioxyphenyl)-2-butylamine hydrochloride (MBDB)(CAS DataBase Reference)
• NIST Chemistry Reference: ((±))-N-Methyl-1-(3,4-methylenedioxyphenyl)-2-butylamine hydrochloride (MBDB)(128767-12-4)
• EPA Substance Registry System: ((±))-N-Methyl-1-(3,4-methylenedioxyphenyl)-2-butylamine hydrochloride (MBDB)(128767-12-4)

Safety Data

• Hazard Codes: F,T
• Statements: 11-23/24/25-39/23/24/25
• Safety Statements: 16-36/37-45
• RIDADR: UN1230 - class 3 - PG 2 - Methanol, solution
• WGK Germany: 1
• Hazardous Substances Data: 128767-12-4(Hazardous Substances Data)

Usage

Uses

Used in Clinical Toxicology and Forensic Analysis:
MBDB is used as a certified solution standard for the identification and quantification of the substance in biological samples. This application is crucial in clinical toxicology and forensic analysis to determine the presence and concentration of MBDB in cases of drug overdose, intoxication, or criminal investigations.
Used in Urine Drug Testing:
MBDB is employed as a reference substance in urine drug testing to detect and measure the levels of the drug in individuals suspected of drug abuse. This application aids in monitoring and managing substance abuse, ensuring compliance with drug testing protocols, and supporting rehabilitation efforts.
Used in Pharmaceutical Research:
As a structural analog of MDMA, MBDB is used in pharmaceutical research to study its pharmacological properties, potential therapeutic applications, and mechanisms of action. This research can contribute to the development of new drugs with similar effects but improved safety profiles or to better understand the risks and benefits associated with the use of substances like MBDB.
Used in Analytical Chemistry (LC/MS or GC/MS):
MBDB serves as a solution standard in liquid chromatography-mass spectrometry (LC/MS) and gas chromatography-mass spectrometry (GC/MS) applications. These techniques are essential in the analysis of complex mixtures, identification of unknown compounds, and quantification of target substances in various samples, including environmental, pharmaceutical, and biological matrices.

Upstream product

• 107447-03-0 1-(3,4-methylenedioxyphenyl)-2-butanamine 
• 16929-04-7 (E)-5-(but-1-en-1-yl)benzo[d][1,3]dioxole 
• 1211-65-0 1-(3,4-Methylenedioxyphenyl)-2-nitro-1-butene 
• 120-57-0 piperonal 
• 2635-13-4 1,2-(methylenedioxy)-4-bromobenzene 
• 23023-13-4 1-(1,3-benzodioxol-5-yl)butan-2-one 
• 74-89-5 methylamine 
• 929532-16-1 N-(1-Benzo[1,3]dioxol-5-ylmethyl-propyl)-formamide 

Relevant articles and documents

Comparative potencies of 3,4-methylenedioxymethamphetamine (MDMA) analogues as inhibitors of [3H]noradrenaline and [3H]5-HT transport in mammalian cell lines

Background and purpose: Illegal 'ecstasy' tablets frequently contain 3,4-methylenedioxymethamphetamine (MDMA)-like compounds of unknown pharmacological activity. Since monoamine transporters are one of the primary targets of MDMA action in the brain, a number of MDMA analogues have been tested for their ability to inhibit [3H]noradrenaline uptake into rat PC12 cells expressing the noradrenaline transporter (NET) and [3H]5-HT uptake into HEK293 cells stably transfected with the 5-HT transporter (SERT). Experimental approach: Concentration-response curves for the following compounds at both NET and SERT were determined under saturating substrate conditions: 4-hydroxy-3-methoxyamphetamine (HMA), 4-hydroxy-3-methoxymethamphetamine (HMMA), 3,4-methylenedioxy-N-hydroxyamphetamine (MDOH), 2,5-dimethoxy-4- bromophenylethylamine (2CB), 3,4-dimethoxymethamphetamine (DMMA), 3,4-methylenedioxyphenyl-2-butanamine (BDB), 3,4-methylenedioxyphenyl-N-methyl- 2-butanamine (MBDB) and 2,3-methylenedioxymethamphetamine (2,3-MDMA). Key results: 2,3-MDMA was significantly less potent than MDMA at SERT, but equipotent with MDMA at NET. 2CB and BDB were both significantly less potent than MDMA at NET, but equipotent with MDMA at SERT. MBDB, DMMA, MDOH and the MDMA metabolites HMA and HMMA, were all significantly less potent than MDMA at both NET and SERT. Conclusions and implications: This study provides an important insight into the structural requirements of MDMA analogue affinity at both NET and SERT. It is anticipated that these results will facilitate understanding of the likely pharmacological actions of structural analogues of MDMA.

HENRY CONDENSATION AT HIGH PRESSURES. 1. SYNTHESIS OF 1-(3,4-METHYLENEDIOXYPHENYL)-2-NITRO-1-BUTENE AND AN IMPROVED SYNTHESIS OF 1-(3,4-METHYLENEDIOXYPHENYL)-2-METHYLAMINOBUTANE

The hitherto inaccessible nitroolefin (VII), which is the most convenient intermediate for the synthesis of the psychotropic amine (VIII), has been obtained by the direct condensation at high pressures (up to 1500 MPa) of piperonal (V) with 1-nitropropane (VI).The structure of (VII) was confirmed by direct synthesis from pyrocatechol (X).The amine (VIII) was obtained in three steps from (VII).This synthesis of (VIII) is shorter than that previously reported.